Prevalence of tuberculosis in Shabwah Governorate, Yemen: A cross-sectional study
Keywords:Pulmonary tuberculosis, Extrapulmonary tuberculosis, Acid fast bacilli, Prevalence
Background: There is a lack of data on current tuberculosis (TB) burden in Shabwah Governorates in Yemen. This study aimed to investigate the prevalence, epidemiology, and outcomes of TB disease in Shabwah Governorate, Yemen. Materials and Methods: This cross-sectional study was conducted at the National TB Program (NTP) Center in Ataq City, Shabwah Governorate, Yemen. The study involved TB patients of different ages who were notified at the center between January 1, 2021, and December 31, 2021. Results: We involved a total of 123 new active TB cases, including 86 (69.9%) with pulmonary TB (PTB) and 37 (30.1%) with extrapulmonary TB (EPTB). The total prevalence of TB disease during the year 2021 was 14.5 new TB cases per 100,000 population, while the median age of the study population was 34 years. The majority of the cases (23.6%) belonged to age group 15–24 years. There was a slightly higher preponderance of males 54.5% (n=67). EPTB was detected in 37 (30.1%) patients with lymph node TB being the most common manifestation [17 (46.0%)]. All patients received four-drug anti-TB therapies for 6–12 months. Most patients 111 (90.3%) were cured, and 2 (1.6%) patients died during the course of the disease, while 10 (8.1%) patients were lost during follow-up. Conclusion: The prevalence of TB in Shabwah Governorate was 14.5/100,000 population. Male patients and younger age groups were more affected, while the lymph nodes were the main extrapulmonary sites involved and the cure rate was 90.2%. The results of the study indicate the need to revise the notification form for active TB cases and to expand NTP activities to focus on targeted screening for active TB cases in high-risk groups to close the gap in unidentified TB cases.
How to Cite
Copyright (c) 2022 Hesham Hezam, Saleh Humaidah
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.